• University of Warwick Featured PhD Programmes
  • University of Leicester Featured PhD Programmes
  • University of Glasgow Featured PhD Programmes
  • Ross University School of Veterinary Medicine Featured PhD Programmes
  • King Abdullah University of Science and Technology (KAUST) Featured PhD Programmes
  • Brunel University London Featured PhD Programmes
University of Manchester Featured PhD Programmes
Imperial College London Featured PhD Programmes
Cranfield University Featured PhD Programmes
Macquarie University Featured PhD Programmes
Lancaster University Featured PhD Programmes

4-year BBSRC DTP Industrial CASE Studentship - Novel factors underlying gut-brain-pancreatic cross talk

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr F M Gribble
    Dr F Reimann
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (Students Worldwide)
    Funded PhD Project (Students Worldwide)

About This PhD Project

Project Description

Cambridge BBSRC DTP Industrial CASE Studentship, partnered with Medimmune/AstraZeneca

“Novel factors underlying gut-brain-pancreatic cross talk”

University of Cambridge Metabolic Research Laboratories and Medimmune/AstraZeneca

Application deadline – January 30th 2016
Interviews – February 17th 2016
Start date - October 2016

A 4-year BBSRC DTP Industrial CASE Studentship is available to work between the laboratories of Professor Fiona Gribble and Dr Frank Reimann at the Wellcome Trust–MRC Institute of Metabolic Science (University of Cambridge) and Dr Lutz Jermutus of Medimmune/AstraZeneca, currently located a short distance away at Granta Park. The Gribble/Reimann laboratory is internationally recognised for introducing innovative strategies to analyse the cellular and molecular biology of gut (entero-) endocrine cells. Medimmune/AstraZeneca has an active development pipeline of biologics in the field of metabolic disease, with a specific focus of interest on therapies based around gut hormones. The project will build on existing strong links that Medimmune/AstraZeneca has developed with the Gribble/Reimann laboratory and the University of Cambridge Metabolic Research Laboratories.

This project aims to identify novel gut peptides hypothesised to contribute to the resolution of type 2 diabetes observed in people undergoing gastric bypass surgery. Gut hormones underlie the coordination of post-prandial nutrient disposition and appetite. They are released from enteroendocrine cells located in the intestinal epithelium and are differentially secreted in states of fasting and refeeding. Gut hormones have a proven track record as therapeutic agents, exemplified by glucagon-like peptide-1 mimetics that used for the treatment of type 2 diabetes and obesity. Gut peptides will be identified using the combined power of RNA sequencing and Mass-Spectrometry (MS), and quantified using MS-based technologies in the Core Biochemical Assay Laboratory. The project will explore mechanisms underlying peptide secretion and will use the peptide engineering and phenotyping expertise of the Medimmune/AstraZeneca laboratories to assess metabolic effects in model systems.

Share this page:

Cookie Policy    X